ALK upgrades guidance after positive Q3 report
The allergy group now expects organic revenue growth of 11-12 percent compared to previous expectations of 10-12 percent.
by marketwire, translated by catherine brett and daniel pedersen
ALK has done better than antcipated on both its top and bottom lines, boosted by surpringsly strong sales of allergy drugs.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Sydbank: Expanded ALK approval is good news
For subscribers
.jpg&w=384&q=75)
